

# Nancy E Davidson

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11116557/nancy-e-davidson-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

223  
papers

37,504  
citations

81  
h-index

193  
g-index

243  
ext. papers

42,083  
ext. citations

8.4  
avg, IF

6.74  
L-index

#	Paper	IF	Citations
223	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3938-3958	2.2	11
222	Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists. <i>Cancer Investigation</i> , <b>2021</b> , 39, 21-24	2.1	
221	Optimal adjuvant endocrine therapy for breast cancer. <i>Lancet Oncology</i> , <b>2021</b> , 22, 1357-1358	21.7	0
220	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. <i>JAMA Oncology</i> , <b>2020</b> , 6, 505-511	13.4	27
219	Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma. <i>Scientific Reports</i> , <b>2020</b> , 10, 11487	4.9	9
218	The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5543-5545	12.9	3
217	Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study. <i>Cancer</i> , <b>2020</b> , 126, 5239-5246	6.4	
216	Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3152-3165	2.2	63
215	Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 641-643	9.7	2
214	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 423-438	2.2	218
213	Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. <i>Oncogene</i> , <b>2019</b> , 38, 390-405	9.2	68
212	CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. <i>Nature Communications</i> , <b>2019</b> , 10, 5114	17.4	32
211	Gonadotropin-Releasing Hormone (GnRH) Agonists for Fertility Preservation: Is POEMS the Final Verse?. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 107-108	9.7	1
210	HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 1388-1401	7.5	38
209	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 122-137	59.2	270
208	Incident Cancer in Cancer Survivors-When Cancer Lurks in the Background. <i>JAMA Oncology</i> , <b>2018</b> , 4, 836-837	13.4	1
207	Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth. <i>Journal of Biological Chemistry</i> , <b>2018</b> , 293, 1120-1137	5.4	39

206	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2804-2807	2.2	59
205	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , <b>2018</b> , 14, 501-504	3.1	19
204	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2736-2740	2.2	103
203	Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood. <i>Scientific Reports</i> , <b>2018</b> , 8, 17313	4.9	15
202	AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health. <i>Cancer Prevention Research</i> , <b>2018</b> , 11, 735-778	3.2	19
201	Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. <i>Cancer Research</i> , <b>2018</b> , 78, 6209-6222	10.1	35
200	Optimal duration of trastuzumab for early HER2-positive breast cancer. <i>Lancet, The</i> , <b>2017</b> , 389, 1167-1168	4.0	1
199	Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases. <i>JAMA Oncology</i> , <b>2017</b> , 3, 666-671	13.4	95
198	Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2691-2701	12.9	84
197	Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 43-51	12.9	44
196	New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1126-1131	12.9	10
195	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e653-e706	21.7	106
194	Practical Approach to Triple-Negative Breast Cancer. <i>Journal of Oncology Practice</i> , <b>2017</b> , 13, 293-300	3.1	45
193	A metastasis biomarker (MetaSite Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. <i>Npj Breast Cancer</i> , <b>2017</b> , 3, 42	7.8	26
192	Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. <i>Breast Cancer Research</i> , <b>2017</b> , 19, 60	8.3	80
191	Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression. <i>Oncotarget</i> , <b>2017</b> , 8, 81737-81753	3.3	24
190	Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 4963-4965	12.9	3
189	WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 92	8.3	32

188	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2925-34	2.2	384
187	Breast cancer: The 21-gene recurrence score - biology remains at the forefront. <i>Nature Reviews Clinical Oncology</i> , <b>2016</b> , 13, 470-2	19.4	3
186	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1689-701	2.2	179
185	Transforming Cancer Prevention through Precision Medicine and Immune-oncology. <i>Cancer Prevention Research</i> , <b>2016</b> , 9, 2-10	3.2	101
184	Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1580-3	2.2	23
183	Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1130-7	12.9	144
182	Conquering Metastatic Breast Cancer. <i>Journal of Oncology Practice</i> , <b>2016</b> , 12, 11-2	3.1	1
181	Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2016</b> , 35, 23-32	7.1	18
180	Reply to C. Shah et al. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1824-5	2.2	
179	AACR Cancer Progress Report 2016. <i>Clinical Cancer Research</i> , <b>2016</b> , 22 Suppl 19, S1-S137	12.9	27
178	Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5362-5369	12.9	42
177	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2563-77	2.2	599
176	Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 5082-5091	12.9	79
175	MCF-7 cells--changing the course of breast cancer research and care for 45 years. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	107
174	Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2353-60	2.2	135
173	A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer. <i>Hormones and Cancer</i> , <b>2015</b> , 6, 214-24	5	18
172	Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1533-46	10.3	1122
171	Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a Parity-Induced Hypermethylation of Igf1r That Persists Long after Parturition. <i>Cancer Prevention Research</i> , <b>2015</b> , 8, 1000-9	3.3	15

170	Developing in vitro models of human ductal carcinoma in situ from primary tissue explants. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 153, 311-21	4.4	16
169	Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3938-44	2.2	158
168	The molecular landscape of premenopausal breast cancer. <i>Breast Cancer Research</i> , <b>2015</b> , 17, 104	8.3	38
167	Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). <i>British Journal of Cancer</i> , <b>2015</b> , 113, 1651-7	8.7	34
166	Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. <i>Breast</i> , <b>2015</b> , 24 Suppl 2, S120-5	3.6	15
165	Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. <i>Meta Gene</i> , <b>2015</b> , 4, 129-41	0.7	14
164	Adjuvant ovarian suppression in premenopausal breast cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 436-46	59.2	462
163	The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. <i>Breast Cancer Research</i> , <b>2015</b> , 17, 133	8.3	17
162	Can circulating tumor cells predict resistance in metastatic breast cancer?. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2421-3	12.9	9
161	Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. <i>Cancer Research</i> , <b>2014</b> , 74, 1463-74	10.1	89
160	Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2959-66	2.2	780
159	Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2255-69	2.2	545
158	Epigenetic reprogramming in breast cancer: from new targets to new therapies. <i>Annals of Medicine</i> , <b>2014</b> , 46, 397-408	1.5	18
157	Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3307-29	2.2	185
156	Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 146, 99-108	4.4	40
155	Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2100-8	2.2	129
154	Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2078-99	2.2	270
153	Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3744-52	2.2	572

152	A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 949-61	12.5	51
151	Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 229ra41	17.5	63
150	Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms. <i>Oncology Nursing Forum</i> , <b>2014</b> , 41, 660-8	1.7	20
149	Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. <i>Cellular and Molecular Life Sciences</i> , <b>2014</b> , 71, 1549	10.3	12
148	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , <b>2013</b> , 24, 2206-23	10.3	2048
147	Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer. <i>Breast</i> , <b>2013</b> , 22 Suppl 2, S165-70	3.6	18
146	Reduced formation of depurinating estrogen-DNA adducts by sulforaphane or KEAP1 disruption in human mammary epithelial MCF-10A cells. <i>Carcinogenesis</i> , <b>2013</b> , 34, 2587-92	4.6	29
145	Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 961-5	2.2	414
144	Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831. <i>Cancer</i> , <b>2013</b> , 119, 2675-82	6.4	39
143	A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 701-10	9.7	353
142	Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. <i>Carcinogenesis</i> , <b>2013</b> , 34, 1196-207	4.6	74
141	Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 4008-16	12.9	21
140	Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 1281-9	12.9	46
139	Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 5798-807	12.9	18
138	Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2115-22	2.2	95
137	Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2942-62	2.2	230
136	Integrated proteomic and metabolic analysis of breast cancer progression. <i>PLoS ONE</i> , <b>2013</b> , 8, e76220	3.7	21
135	Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 131, 777-89	4.4	96

134	Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 132, 175-87	4.4	148
133	Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 131, 907-14	4.4	45
132	A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 131, 915-24	4.4	50
131	Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. <i>Amino Acids</i> , <b>2012</b> , 42, 887-98	3.5	61
130	Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3051-7	2.2	68
129	Role of ornithine decarboxylase in regulation of estrogen receptor alpha expression and growth in human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 136, 57-66	4.4	33
128	Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. <i>Cancer</i> , <b>2012</b> , 118, 5937-46	6.4	138
127	Hormonal therapy in breast cancer: a model disease for the personalization of cancer care. <i>Molecular Oncology</i> , <b>2012</b> , 6, 222-36	7.9	39
126	Hematopoietic growth factors: personalization of risks and benefits. <i>Molecular Oncology</i> , <b>2012</b> , 6, 237-47	7.9	10
125	Novel insight into KLF4 proteolytic regulation in estrogen receptor signaling and breast carcinogenesis. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 13584-97	5.4	26
124	Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 134, 683-92	4.4	55
123	TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 134, 751-7	4.4	10
122	Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 406-14	9.7	65
121	Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 159-62	9.7	61
120	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 2736-41	11.5	81
119	Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1005-1005	2.2	9
118	Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3366-73	2.2	555
117	Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4491-7	2.2	202

116	Epigenetics in breast cancer: what's new?. <i>Breast Cancer Research</i> , <b>2011</b> , 13, 225	8.3	92
115	Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 127, 153-62	4.4	15
114	Monoclonal antibody cocktail as an enrichment tool for acetylome analysis. <i>Analytical Chemistry</i> , <b>2011</b> , 83, 3623-6	7.8	24
113	C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 651-9	2.2	49
112	Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7194-203	12.9	18
111	American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3939-42	2.2	47
110	Inhibition of histone deacetylases. <i>Methods in Molecular Biology</i> , <b>2011</b> , 791, 297-311	1.4	4
109	HER2-targeted therapies: how far we've come—and where we're headed. <i>Oncology</i> , <b>2011</b> , 25, 425-6	1.8	5
108	The American Society of Clinical Oncology Cancer Foundation Grants Program: a 25-year report and a look toward the future. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1616-21	2.2	5
107	American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3784-96	2.2	565
106	HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4307-15	2.2	175
105	Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling. <i>Carcinogenesis</i> , <b>2010</b> , 31, 382-7	4.6	58
104	Multiparametric magnetic resonance imaging, spectroscopy and multinuclear ( <sup>23</sup> Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. <i>Academic Radiology</i> , <b>2010</b> , 17, 1477-85	4.3	42
103	Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. <i>Lancet Oncology</i> , <b>2010</b> , 11, 55-65	21.7	1065
102	The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2010</b> , 65, 1067-81	3.5	34
101	Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 120, 581-92	4.4	102
100	Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 124, 585-91	4.4	63
99	Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. <i>Proteomics</i> , <b>2010</b> , 10, 1029-39	4.8	41



98	Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5319-24	2.2	285
97	Reply to J.M. Guinebretiere and L. Arnould et al. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2734-2735	2.2	1
96	The silent estrogen receptor--can we make it speak?. <i>Cancer Biology and Therapy</i> , <b>2009</b> , 8, 485-96	4.6	14
95	Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 7693-7700	12.9	21
94	Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5911-8	2.2	178
93	Epigenetics meets estrogen receptor: regulation of estrogen receptor by direct lysine methylation. <i>Endocrine-Related Cancer</i> , <b>2009</b> , 16, 319-23	5.7	18
92	Small beginnings: do they matter? The importance of lymphovascular invasion in early breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 698-9	9.7	1
91	Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2816-22	2.2	13
90	Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 117, 443-51	4.4	54
89	What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?. <i>Current Oncology Reports</i> , <b>2009</b> , 11, 45-50	6.3	9
88	What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?. <i>Current Breast Cancer Reports</i> , <b>2009</b> , 1, 42-47	0.8	
87	Postoperative endocrine therapy for invasive breast cancer. <i>Cancer Treatment and Research</i> , <b>2009</b> , 151, 139-61	3.5	3
86	Weekly paclitaxel in the adjuvant treatment of breast cancer. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 1663-71	59.2	701
85	Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4063-71	2.2	271
84	A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 6277-83	12.9	59
83	Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1948-55	2.2	156
82	Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. <i>Molecular Cancer Research</i> , <b>2008</b> , 6, 873-83	6.6	131
81	Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4092-9	2.2	82

80	Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 1938-46	12.9	173
79	Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1231-8	2.2	424
78	Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2473-81	2.2	190
77	Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. <i>Cancer Research</i> , <b>2007</b> , 67, 5337-44	10.1	83
76	Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 2666-76	59.2	2529
75	PI3 kinase activation and response to Trastuzumab Therapy: what@ neu with herceptin resistance?. <i>Cancer Cell</i> , <b>2007</b> , 12, 297-9	24.3	41
74	Aromatase inhibitors for breast cancer. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2007</b> , 8, 215-28	10.5	15
73	Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2006-11	2.2	112
72	How we maintain bone health in early-stage breast cancer patients on aromatase inhibitors. <i>Journal of Oncology Practice</i> , <b>2007</b> , 3, 323-5	3.1	1
71	Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. <i>Cancer Biology and Therapy</i> , <b>2007</b> , 6, 64-9	4.6	127
70	Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. <i>Molecular Cancer Therapeutics</i> , <b>2007</b> , 6, 1013-21	6.1	256
69	Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. <i>Carcinogenesis</i> , <b>2007</b> , 28, 1485-90	4.6	256
68	Epigenetic regulation as a new target for breast cancer therapy. <i>Cancer Investigation</i> , <b>2007</b> , 25, 659-65	2.1	64
67	Epigenetic Regulation as a New Target for Breast Cancer Therapy. <i>Translational Medicine Series</i> , <b>2007</b> , 285-296		
66	Adjuvant hormonal therapy for premenopausal women with breast cancer. <i>Seminars in Oncology</i> , <b>2006</b> , 33, 657-63	5.5	19
65	Polyamine analogues down-regulate estrogen receptor alpha expression in human breast cancer cells. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 19055-63	5.4	36
64	Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 4949-51	2.2	4
63	Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. <i>Cancer Research</i> , <b>2006</b> , 66, 6370-8	10.1	173

62	Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 3306-10	12.9	110
61	HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 3032-8	2.2	376
60	Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 2392-4; author reply 2394-5	2.2	15
59	Estrogen carcinogenesis in breast cancer. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 270-82	59.2	1296
58	Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196. <i>Clinical Breast Cancer</i> , <b>2006</b> , 6, 525-9	3	7
57	Silencing estrogen receptor alpha in breast cancer cells. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 848-9	4.6	5
56	Anticancer activities of novel chalcone and bis-chalcone derivatives. <i>Bioorganic and Medicinal Chemistry</i> , <b>2006</b> , 14, 3491-5	3.4	305
55	Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. <i>Breast Cancer Research and Treatment</i> , <b>2006</b> , 99, 295-300	4.4	77
54	Role of p53/p21(Waf1/Cip1) in the regulation of polyamine analogue-induced growth inhibition and cell death in human breast cancer cells. <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 1006-13	4.6	15
53	Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 1262-71	9.7	918
52	Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 1673-84	59.2	4284
51	Molecular mechanisms of polyamine analogs in cancer cells. <i>Anti-Cancer Drugs</i> , <b>2005</b> , 16, 229-41	2.4	68
50	Of Snail, mice, and women. <i>Cancer Cell</i> , <b>2005</b> , 8, 173-4	24.3	25
49	Protein phosphatase 2A regulates estrogen receptor alpha (ER) expression through modulation of ER mRNA stability. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 29519-24	5.4	35
48	Case records of the Massachusetts General Hospital. Case 35-2005. A 56-year-old woman with breast cancer and isolated tumor cells in a sentinel lymph node. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 2177-85	59.2	3
47	Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. <i>Molecular Endocrinology</i> , <b>2005</b> , 19, 1740-51		136
46	Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 18302-10	5.4	99
45	Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 5973-82	2.2	184

44	Spermine oxidase SMO(PAOh1), Not N1-acetylpolyamine oxidase PAO, is the primary source of cytotoxic H2O2 in polyamine analogue-treated human breast cancer cell lines. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 39843-51	5.4	87
43	Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 1304-12	4.6	30
42	What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?. <i>Oncologist</i> , <b>2004</b> , 9, 507-17	5.7	32
41	Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applications. <i>Technology in Cancer Research and Treatment</i> , <b>2004</b> , 3, 543-50	2.7	36
40	Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 3700-4	2.2	108
39	DJvu for breast cancer two?. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 497-9	9.7	3
38	Induction of spermidine/spermine N1-acetyltransferase in breast cancer tissues treated with the polyamine analogue N1, N11-diethylnorspermine. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2004</b> , 54, 122-6	3.5	27
37	Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 4683-90	2.2	174
36	Regulation of polyamine analogue cytotoxicity by c-Jun in human MDA-MB-435 cancer cells. <i>Molecular Cancer Research</i> , <b>2004</b> , 2, 81-8	6.6	12
35	Trastuzumab in breast cancer. <i>Oncology</i> , <b>2004</b> , 18, 1117-28; discussion 1131-2, 1137-8	1.8	21
34	Regulation of Polyamine Analogue Cytotoxicity by c-Jun in Human MDA-MB-435 Cancer Cells. <i>Molecular Cancer Research</i> , <b>2004</b> , 2, 81-88	6.6	28
33	Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. <i>Cancer Biology and Therapy</i> , <b>2003</b> , 2, 552-6	4.6	78
32	A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2-Deoxycytidine. <i>Breast Cancer Research and Treatment</i> , <b>2003</b> , 81, 177-86	4.4	138
31	Methyl-group dietary intake and risk of breast cancer among African-American women: a case-control study by methylation status of the estrogen receptor alpha genes. <i>Cancer Causes and Control</i> , <b>2003</b> , 14, 827-36	2.8	45
30	New findings about endocrine therapy for breast cancer. <i>Breast</i> , <b>2003</b> , 12, 368-72	3.6	2
29	The follow-up of breast cancer. <i>Seminars in Oncology</i> , <b>2003</b> , 30, 338-48	5.5	48
28	The biology of breast carcinoma. <i>Cancer</i> , <b>2003</b> , 97, 825-33	6.4	155
27	Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. <i>Journal of Medicinal Chemistry</i> , <b>2003</b> , 46, 2813-5	8.3	249

26	A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 1793-802	59.2	1500
25	Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 1431-9	2.2	1245
24	A novel polyamine analog inhibits growth and induces apoptosis in human breast cancer cells. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 2769-77	12.9	49
23	A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 5922-8	12.9	71
22	Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 855-7	9.7	323
21	Use of SERMs for the adjuvant therapy of early-stage breast cancer. <i>Annals of the New York Academy of Sciences</i> , <b>2001</b> , 949, 80-8	6.5	4
20	Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , <b>2001</b> , 6, 183-92	2.4	66
19	Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. <i>Lancet, The</i> , <b>2001</b> , 357, 1335-6	40	295
18	Ovarian ablation as adjuvant therapy for breast cancer. <i>Seminars in Oncology</i> , <b>2001</b> , 28, 322-331	5.5	17
17	Primary systemic therapy in operable breast cancer. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 1558-69	2.2	67
16	American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 1080-2	2.2	214
15	Expression of DNA methyl-transferase (DMT) and the cell cycle in human breast cancer cells. <i>Oncogene</i> , <b>1999</b> , 18, 7453-61	9.2	35
14	The biology of breast cancer. <i>Hematology/Oncology Clinics of North America</i> , <b>1999</b> , 13, 311-32	3.1	27
13	Apoptosis and Breast Cancer <b>1999</b> , 291-303		1
12	The loss of estrogen and progesterone receptor gene expression in human breast cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , <b>1998</b> , 3, 85-94	2.4	137
11	Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression. <i>Oncogene</i> , <b>1998</b> , 17, 577-83	9.2	34
10	The regulation of estrogen receptor expression and function in human breast cancer. <i>Cancer Treatment and Research</i> , <b>1998</b> , 94, 255-78	3.5	5
9	Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2-deoxycytidine-induced cytotoxicity in human breast cancer cells. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 32260-6	5.4	122

8	Apoptosis in hormone-responsive malignancies. <i>Advances in Pharmacology</i> , <b>1997</b> , 41, 553-83	5-7	7
7	Regulation of estrogen receptor alpha function in breast cancer. <i>Critical Reviews in Oncogenesis</i> , <b>1997</b> , 8, 29-46	1-3	33
6	Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. <i>Nature Genetics</i> , <b>1994</b> , 7, 536-40	36-3	1005
5	Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>1993</b> , 28, 277-84	4-4	10
4	Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. <i>Journal of the National Cancer Institute</i> , <b>1990</b> , 82, 570-4	9-7	37
3	Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. <i>Molecular Endocrinology</i> , <b>1988</b> , 2, 543-55		381
2	Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. <i>Molecular Endocrinology</i> , <b>1987</b> , 1, 216-23		239
1	Proteomic and Transcriptomic Profiling Identifies Mediators of Anchorage-Independent Growth and Roles of Inhibitor of Differentiation Proteins in Invasive Lobular Breast Cancer		1